Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 1266Specimen Handling 927Magnetic Resonance Spectroscopy 835Carboplatin 825Cyclophosphamide 804Cisplatin 726Nivolumab 666Paclitaxel 630Radiotherapy 609Gemcitabine 571Biopsy 561Bevacizumab 481Dexamethasone 439fludarabine 409Docetaxel 377venetoclax 368Oxaliplatin 364Fluorouracil 356Capecitabine 355atezolizumab 351durvalumab 334Rituximab 332Drug Therapy 325Doxorubicin 317Radiosurgery 315Blood Specimen Collection 310Standard of Care 310Pemetrexed 305Ipilimumab 297Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glutamyl Aminopeptidase × 1 year × Clear all
NCT05415527 2026-01-29

OPTIMOVA

Institut Bergonié

Phase NA Active not recruiting
25 enrolled
Gynecologic

Ovarian Neoplasms

NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT05441163 2025-06-24

ProActIF-01

Institut Curie

Phase NA Recruiting
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡